Sarah Case
Family · Deland, FLNPI 1922636851
Payments from drug & device makers
Across 240 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Amgen$592
- Lilly USA, LLC$388
- Novartis$279
- AstraZeneca$173
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,068 |
| AbbVie | 44 | $1,041 |
| Amgen | 26 | $592 |
| Lilly USA, LLC | 17 | $388 |
| Novartis | 18 | $279 |
| AstraZeneca | 11 | $173 |
| Bayer | 7 | $147 |
| Pfizer | 6 | $143 |
| Axsome Therapeutics, Inc. | 5 | $127 |
| Exact Sciences | 5 | $95 |
| Boehringer Ingelheim | 5 | $84 |
| KARL Storz Endoscopy-america | 1 | $74 |
| Impel Pharmaceuticals Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 1 | $67 |
| Corcept Therapeutics | 2 | $46 |
| Johnson & Johnson(2 entities) | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Shield Therapeutics Inc | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Radius Health, Inc. | 1 | $29 |
| Antares Pharma, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Hollister Incorporated | 1 | $21 |
| Abbott | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,829 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $78,722 |
| EliquisApixaban | 23 | $30,065 |
| FarxigaDapagliflozin Propanediol | 30 | $29,224 |
| MounjaroTirzepatide | 19 | $28,946 |
| JanuviaSitagliptin Phosphate | 13 | $15,878 |
| JardianceEmpagliflozin | 15 | $12,219 |
| Levothyroxine Sodium | 130 | $1,335 |
| Midodrine Hcl | 13 | $1,259 |
| Rosuvastatin Calcium | 109 | $1,144 |
| Omeprazole | 55 | $1,141 |
| Atorvastatin Calcium | 120 | $1,121 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,100 |
| Gabapentin | 50 | $821 |
| Lisinopril | 100 | $769 |
| Cyclobenzaprine Hcl | 34 | $660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,068 | $78,72267 claims |
| PfizerEliquis | $143 | $30,06523 claims |
| AstraZenecaFarxiga | $173 | $29,22430 claims |
| Lilly USA, LLCMounjaro | $388 | $28,94619 claims |
| Boehringer IngelheimJardiance | $84 | $12,21915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Deland
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.